MAPT and Alzheimer disease: Before that, preclinical stage AD biomarkers were categorized as Stage 1: amyloidosis by PET and CSF Aβ42 analysis, and Stage 2: Neurodegeneration by PET and CSF tau (Jack et al., 2010).